Dabigatran (Dabiran) is a novel oral direct thrombin inhibitor which reversibly block the catalytic site of Thrombin and produce rapid anticoagulation action.
Indication
- Reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).
- Reduce the risk of deep vein thrombosis and pulmonary embolism.
Dosage
- Prevention of stroke and SEE in adult patients with NVAF with one or more risk factors (SPAF).
- The recommended daily dose of Dabigatran is 300 mg taken as one 150 mg capsule twice daily.
